• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

共刺激结构域促进 CAR-T 细胞抗肿瘤疗效的分子机制。

Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy.

机构信息

Cancer Institute, the First Clinical Medical College, Xuzhou Medical University, Xuzhou, Jiangsu, China; Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

出版信息

Biochem Pharmacol. 2024 Sep;227:116439. doi: 10.1016/j.bcp.2024.116439. Epub 2024 Jul 18.

DOI:10.1016/j.bcp.2024.116439
PMID:39032532
Abstract

Chimeric antigen receptor (CAR)-engineered T cells have been defined as 'living drug'. Adding a co-stimulatory domain (CSD) has enhanced the anti-hematological effects of CAR-T cells, thereby elevating their viability for medicinal applications. Various CSDs have helped prepare CAR-T cells to study anti-tumor efficacy. Previous studies have described and summarized the anti-tumor efficacy of CAR-T cells obtained from different CSDs. However, the underlying molecular mechanisms by which different CSDs affect CAR-T function have been rarely reported. The role of CSDs in T cells has been significantly studied, but whether they can play a unique role as a part of the CAR structure remains undetermined. Here, we summarized the effects of CSDs on CAR-T signaling pathways based on the limited references and speculated the possible mechanism depending on the specific characteristics of CAR-T cells. This review will help understand the molecular mechanism of CSDs in CAR-T cells that exert different anti-tumor effects while providing potential guidance for further interventions to enhance anti-tumor efficacy in immunotherapy.

摘要

嵌合抗原受体 (CAR)-修饰的 T 细胞已被定义为“活药物”。添加共刺激结构域 (CSD) 增强了 CAR-T 细胞的抗血液肿瘤作用,从而提高了其在医学应用中的活力。各种 CSD 有助于制备 CAR-T 细胞以研究抗肿瘤功效。先前的研究已经描述和总结了来自不同 CSD 的 CAR-T 细胞的抗肿瘤功效。然而,不同 CSD 影响 CAR-T 功能的潜在分子机制很少有报道。CSD 在 T 细胞中的作用已经得到了充分的研究,但它们是否可以作为 CAR 结构的一部分发挥独特的作用仍不确定。在这里,我们根据有限的参考文献总结了 CSD 对 CAR-T 信号通路的影响,并根据 CAR-T 细胞的具体特征推测了可能的机制。本综述将有助于了解 CSD 在 CAR-T 细胞中发挥不同抗肿瘤作用的分子机制,同时为进一步干预以增强免疫疗法中的抗肿瘤疗效提供潜在指导。

相似文献

1
Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy.共刺激结构域促进 CAR-T 细胞抗肿瘤疗效的分子机制。
Biochem Pharmacol. 2024 Sep;227:116439. doi: 10.1016/j.bcp.2024.116439. Epub 2024 Jul 18.
2
High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy.基于生物素结合的单体链霉亲和素的第三代 CAR(CD28-4-1BB-CD3-ζ)工程 T 细胞具有高特异性,可用于潜在的肿瘤免疫治疗。
Front Immunol. 2024 Sep 19;15:1448752. doi: 10.3389/fimmu.2024.1448752. eCollection 2024.
3
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.免疫细胞改造:创造更智能嵌合抗原受体 T 细胞的挑战和临床方法。
Front Immunol. 2018 Jul 31;9:1717. doi: 10.3389/fimmu.2018.01717. eCollection 2018.
4
Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.多特异性靶向的合成锚蛋白重复序列嵌合抗原受体。
Clin Cancer Res. 2019 Dec 15;25(24):7506-7516. doi: 10.1158/1078-0432.CCR-19-1479. Epub 2019 Sep 23.
5
Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy.重塑肿瘤免疫微环境以改善基于 CAR-T 细胞的癌症免疫疗法。
Mol Cancer. 2024 Aug 26;23(1):175. doi: 10.1186/s12943-024-02079-8.
6
Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties.嵌合抗原受体 T 细胞携带疱疹病毒进入介质共刺激信号域,表现出抗衰竭特性。
Int J Mol Sci. 2024 Aug 8;25(16):8662. doi: 10.3390/ijms25168662.
7
Effective Targeting of TAG72 Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.通过区域递送 CAR 工程化 T 细胞靶向 TAG72 腹膜卵巢肿瘤。
Front Immunol. 2018 Nov 19;9:2268. doi: 10.3389/fimmu.2018.02268. eCollection 2018.
8
Engineering CAR-T Cells for Next-Generation Cancer Therapy.工程化 CAR-T 细胞用于下一代癌症治疗。
Cancer Cell. 2020 Oct 12;38(4):473-488. doi: 10.1016/j.ccell.2020.07.005. Epub 2020 Jul 30.
9
CAR Cells beyond Classical CAR T Cells: Functional Properties and Prospects of Application.嵌合抗原受体 T 细胞之外的 CAR 细胞:功能特性和应用前景。
Biochemistry (Mosc). 2024 May;89(5):765-783. doi: 10.1134/S0006297924050018.
10
Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.嵌合抗原受体工程 T(CAR-T)细胞和肿瘤特异性 T 细胞的生存时间延长是由抗程序性细胞死亡蛋白 1 单链可变片段产生的 CAR-T 细胞引起的。
Cancer Sci. 2019 Oct;110(10):3079-3088. doi: 10.1111/cas.14169. Epub 2019 Sep 17.

引用本文的文献

1
Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells.结直肠癌中的过继性细胞疗法:嵌合抗原受体T细胞的进展
World J Gastrointest Oncol. 2025 Jul 15;17(7):106723. doi: 10.4251/wjgo.v17.i7.106723.
2
Dap10 co-stimulation enhances the anti-HCC efficacy of NKp30 chimeric antigen receptor T cells.Dap10共刺激增强了NKp30嵌合抗原受体T细胞的抗肝癌疗效。
Transl Oncol. 2025 Jul;57:102425. doi: 10.1016/j.tranon.2025.102425. Epub 2025 May 19.
3
From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapy.
从分子设计到临床转化:癌症免疫治疗中的双靶点嵌合抗原受体T细胞策略
Int J Biol Sci. 2025 Mar 31;21(6):2676-2691. doi: 10.7150/ijbs.108036. eCollection 2025.
4
Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer Immunotherapy.细胞外 pH 值在肿瘤微环境中作为癌症免疫治疗的治疗靶点的新作用。
Cells. 2024 Nov 20;13(22):1924. doi: 10.3390/cells13221924.